Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes.
OBJECTIVE Effects of weight loss on vascular function are unknown . We compared , in the face of similar weight loss over 3 - 6 months , effects of orlistat ( 120 mg t.i.d . , n = 23 ) and placebo ( n = 24 ) on in vivo endothelial function in a high-risk group of obese ( BMI 32.1 + /- 0.4 kg/m(2 ) ) premenopausal nondiabetic women with a history of gestational diabetes . RESEARCH DESIGN AND METHODS Forearm blood flow responses to intra-arterial infusions of acetylcholine ( ACh ) and sodium nitroprusside ( SNP ) , body composition , and serum lipids were determined before and after weight loss . RESULTS Weight loss averaged 7.3 + /- 0.2 kg ( 8.3 + /- 0.1 % ) and 7.4 + /- 0.2 kg ( 8.2 + /- 0.1 % ) of initial body weight in the orlistat and placebo groups , respectively . Forearm and body compositions changed similarly in both groups . Responses to ACh increased by 41 % to the low dose ( 5.9 + /- 0.6 vs. 8.3 + /- 0.3 for flow in the experimental/control arm , P < 0.01 ) and by 33 % to the high dose ( 7.6 + /- 0.8 vs. 10.1 + /- 0.6 , P < 0.001 ) in the orlistat group , but they remained unchanged in the placebo group . The blood flow responses to SNP did not differ significantly between the groups . LDL cholesterol decreased significantly in the orlistat group from 3.5 + /- 0.2 to 3.0 + /- 0.1 mmol/l ( P < 0.01 ) but remained unchanged in the placebo group . Within the orlistat group , the decrease in LDL cholesterol correlated significantly with the improvement in the blood flow response to ACh ( r = -0.44 , P < 0.05 ) . CONCLUSIONS Orlistat but not moderate ( 8 % ) weight loss per se improves endothelial function in women with previous gestational diabetes . This improvement is associated with a lowering of LDL cholesterol by orlistat
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .